For many conditions including immune-related ones, genetics often explains only a small fraction of the differences between ...
Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s preclinical, oral C5aR1 antagonist. This agreement strengthens ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback